March 14th, 2011
AHA Offers Qualified Endorsement of Weight-Loss Surgery
Larry Husten, PHD
For the first time, the AHA has offered a qualified endorsement of bariatric surgery. The scientific statement, published in Circulation, states that bariatric surgery is a relatively safe procedure that can lead to long-term weight loss and significantly improve health in appropriately selected obese patients who have been unable to lose weight nonsurgically.
But, said Paul Poirier, the lead author of the statement, in an AHA press release, “it is not an across-the-board endorsement of bariatric surgery for the severely obese. It is a consensus document that provides expert perspective based on the results of recent scientific studies.”
The statement notes that surgical weight loss can “completely reverse established diabetes mellitus in a large percentage of subjects” and results in improvements in lipids, inflammation, nonalcoholic fatty liver disease, hypertension, sleep apnea, and cardiac function. The report states that “there is increasing, although not definitive, evidence that bariatric surgery provides a significant survival benefit.”
Categories: General, Prevention
Tags: bariatric surgery, obesity, weight loss
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “AHA Offers Qualified Endorsement of Weight-Loss Surgery”
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Celiac-Artery Dissection September 12, 2026A 72-year-old man with hypertension, hyperlipidemia, and a stable ascending aortic aneurysm presented with sudden-onset, severe chest pain. CTA of the chest, abdomen, and pelvis showed a celiac-artery dissection.
- Complete Revascularization Guided by Functional Coronary Angiography in STEMI September 10, 2026Among patients with ST-segment elevation myocardial infarction and multivessel disease, physiology-guided angiography led to a lower risk of major cardiovascular events than conventional angiography-guided treatment.
- Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials September 9, 2026In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common.
- Immediate Ambulatory Electrocardiographic Monitoring in Syncope August 31, 2026Among patients with syncope that remained unexplained after evaluation in the ED, immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care.
- Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism August 31, 2026Catheter-directed thrombolysis led to a lower risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse at 7 days than anticoagulation alone in intermediate-high–risk acute pulmonary embolism.
- Celiac-Artery Dissection September 12, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women

There is no doubt that bariatric surgery is useful in morbidly obese, but the judicious selection of patients ,taking into account their personality profile is of the utmost importance.The so called “complete reversal of diabetes” is yet to be observed on a long term basis.
Competing interests pertaining specifically to this post, comment, or both:
none